Princeton, NJ, USA, June 9, 2015 – The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) held its 20th Annual International Meeting May 16-20, 2015 in Philadelphia. The 2015 Annual International Meeting marked ISPOR’s 20th anniversary and focused on the…
News and Press Releases
Month: June 2015
ISPOR, CELEBRATING 20 YEARS OF GROWTH AND ACHIEVEMENT AT 2015 ANNUAL INTERNATIONAL MEETING, PRESENTS ITS “2015 SCIENTIFIC ACHIEVEMENT AWARDS”
Posted in Announcements, ISPOR News & Press Tagged with: Annual International Meeting, HEOR, ISPOR, ISPOR Awards, Scientific Achievements
ISPOR CELEBRATES A 20-YEAR HISTORY THAT IS SHAPING THE FUTURE OF HEALTH ECONOMICS AND OUTCOMES RESEARCH AT 2015 ANNUAL INTERNATIONAL MEETING
Princeton, NJ, USA, June 2, 2015–The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) held its 20th Annual International Meeting May 16-20, 2015 in Philadelphia. The Meeting marked ISPOR’s 20th anniversary and focused on the theme of Integrating Big Data,…
Archives
- [—] 2018 (49)
- [+] August (2)
- [+] July (3)
- Nurse Telephone Support and Home Telemonitoring Are Cost-Effective in Chronic Heart Failure Management
- Challenging the Status Quo: Report Urges the Use of Local Context to Determine Cost-Effectiveness Thresholds in Low- and Middle-income Countries
- ISPOR Wins 2018 “Power of A” Award for Its Good Practices for Outcomes Research Reports
- [+] June (7)
- Value in Health Impact Demonstrates 5th Consecutive Year of Double-Digit Growth
- ISPOR Announces New Summit on Value Assessment
- Conference Theme and Plenary Speakers Announced for ISPOR Asia Pacific 2018
- A Framework for the Use of Wearable Medical Devices in Regulatory Clinical Trials
- Novel Approach to Assessing US Outpatient Drug Costs for Use in Cost-Effectiveness Analyses
- ISPOR Announces 2018-2019 Board of Directors
- ISPOR 2018 Drew Nearly 4000 Stakeholders in Health Economics and Outcomes Research
- [+] May (22)
- Best Podium and Poster Presentations Awarded at ISPOR 2018
- Strengths and Limitations of Patient Preferences to Inform Regulatory Decisions
- How Much Is the United States Actually Spending on Prescription Drugs?
- Artificial Intelligence: Is It the “Next Big Thing” in Healthcare?
- Addressing Challenges of Value Assessment in Healthcare
- ISPOR Panel Discusses Recommendations and Rationale of “Making Medicines Affordable: A National Imperative”
- ISPOR Presents 2018 Awards for Outstanding Achievement in Health Economics and Outcomes Research
- Digital Health—Help or Hype?
- ISPOR Health Economics and Outcomes Research Competencies Framework™
- Defining Patient-Centeredness in Healthcare
- Moving Beyond Traditional Cost-Effectiveness Analysis
- Reinventing the Future of Knowledge Generation in Healthcare
- Women in Health Economics and Outcomes Research Initiative Held Session at ISPOR 2018
- What Is Patient Experience Data? The Regulatory Perspective
- Real-World Evidence and the Transformational Role of Digital Health
- Rare Diseases: Addressing the Challenges in Diagnosis, Drug Approval, and Patient Access
- Study: Subsidized Payments May Help Foster Demand for HPV Vaccination in Hong Kong
- ISPOR Launches Center for Health Technology Assessment
- ISPOR 2018 Conference to Focus on Real-World Evidence and Digital Health
- ISPOR Recognized for Outstanding Work by Hermes Awards
- ISPOR Announces Patient Representatives Roundtable Chairs and Patient Council Members
- Winning Submissions Published for PhRMA Foundation’s Value Assessment Challenge Awards Program
- [+] April (3)
- [+] March (4)
- [+] February (4)
- New Study Shows Most Women Willing to Accept the Risks of Breast Screening
- ISPOR Special Task Force Provides Recommendations for Measuring and Communicating the Value of Pharmaceuticals and Other Technologies in the US
- ISPOR Announces a Brand Refresh for the Society
- Top 10 Trends Driving Healthcare in 2018
- [+] January (4)
- [+] 2017 (63)
- [+] December (1)
- [+] November (15)
- ISPOR Honored With 6 Stevie® Awards for Women in Business
- ISPOR 20th Annual European Congress Examines the Real Value in Health Care
- Addressing the Digital Divide—mHealth in Cancer Care
- Including the Patient Perspective in Health Care Decision Making
- Best Podium and Poster Presentations Awarded at ISPOR 20th Annual European Congress
- The Evolving Assessment of “Value” in Health Care
- Assessing the Value of New Antibiotics: Creating a Value Assessment Framework
- Real-World Evidence in Health Care Decision Making
- The Changing Landscape for Medical Devices
- ISPOR Establishes New “Women in Health Economics and Outcomes Research” Initiative
- What Is the Future of Health Technology Assessment in Europe?
- Orphan Drugs—Exploring the Challenges of Pricing, Reimbursement, and Funding
- What Is “Unmet Medical Need?”
- How Can Good Research Practice Guidance Improve Health Technology Assessment?
- Finding the “Value” in Value-Based Health Care
- [+] October (1)
- [+] September (6)
- ISPOR Undertakes Competencies Initiative for the Field of Health Economics and Outcomes Research
- Plenary Sessions and Speakers Announced for ISPOR 20th Annual European Congress
- The Voice of the Patient in Latin America
- Latin America Faces Opportunities and Challenges in the Goal to Achieve Universal Health Care Coverage
- Making Real-World Data Studies More Useful for Health Care Decision Making
- ISPOR Latin America Conference to Focus on Improving Health Outcomes Through Stakeholder Engagement
- [+] August (2)
- [+] July (3)
- [+] June (4)
- Value in Health Journal Impact Demonstrates Another Consecutive Year of Double-Digit Growth
- ISPOR Announces Its 6th Latin America Conference Plenary Sessions and Speakers
- ISPOR Announces 2017-2018 Board of Directors
- ISPOR 22nd Annual International Meeting Drew Key Stakeholders and Thought Leaders to Discuss Social and Policy Changes in Health Care
- [+] May (16)
- Is Big Data Eclipsing the Role of Randomized Controlled Trials?
- What Can We Learn From Global Health Care Systems?
- Panel Explores Issue of Real-World Evidence to Inform Health Policies for Medical Devices
- Best Podium and Poster Presentations Awarded at ISPOR 22nd Annual International Meeting
- ISPOR Presents 2017 Scientific and Leadership Awards
- Developing and Paying for Gene Therapies: How to Measure Value?
- New Methodological Approaches to Assess Value of Immuno-Oncology Therapies
- The 21st Century Cures Act: Considering the Implications
- Short- and Long-Term Impact of Medicare Negotiating Drug Prices: A Critical Look at the Policy Proposals
- The Power of Social Network Interventions on Population Health
- The Relationship Between Cost Effectiveness and Affordability in Health Care
- Assessment of Value in Health Care
- Capturing the “Patient Voice” in Health Care
- ISPOR and ISPE Collaborate to Advance Good Practices for Use of Real-World Evidence
- Opening Plenary Session Explores Direction of US Health Policy Changes
- ISPOR 22nd Annual International Meeting to Focus on Social and Policy Change in Health Care
- [+] April (4)
- ISPOR Recognizes Its Volunteer Leaders During National Volunteer Week
- New Study Identifies Notable Differences in How 6 European Health Agencies Assess Real-World Data
- For Women at Risk of Hereditary Breast Cancer, Multigene Test Could Help Extend Life Expectancy
- ISPOR Announces 2017 Scientific Achievement and Leadership Awards
- [+] March (5)
- New Research Findings: Health Costs for Children With Cancer Are Higher Than for Adolescents, Adults
- Introducing Novel Guidelines for Patient Engagement in Research
- ISPOR Publishes New Task Force Report on Constrained Optimization Methods
- ISPOR Announces Plenary Sessions and Speakers For 22nd Annual International Meeting
- ISPOR’s COMMITMENT TO GLOBAL INCLUSIVITY AND SCIENTIFIC EXCELLENCE
- [+] February (4)
- ISPOR INITIATIVE ADVANCES HIGH-QUALITY VALUE ASSESSMENT FRAMEWORKS FOR HEALTH CARE INTERVENTIONS
- “MAPPING STUDIES” IN COST-UTILITY ANALYSES: NEW RECOMMENDATIONS FROM ISPOR TASK FORCE
- ISPOR RELEASES NEW TASK FORCE RECOMMENDATIONS FOR THE DEVELOPMENT OF CLINICIAN-REPORTED OUTCOME ASSESSMENTS
- ISPOR OFFERING NEW, COMPLIMENTARY WEBINAR—“INTRODUCTION TO HEALTH ECONOMICS AND OUTCOMES RESEARCH”
- [+] January (2)
- [+] 2016 (75)
- [+] December (3)
- [+] November (15)
- ISPOR 19th ANNUAL EUROPEAN CONGRESS DREW KEY STAKEHOLDERS AND THOUGHT LEADERS TO DISCUSS ACCESS TO MEDICAL INNOVATIONS
- BEST PODIUM AND POSTER PRESENTATIONS AWARDED AT ISPOR 19TH ANNUAL EUROPEAN CONGRESS
- ISPOR CEO NANCY BERG WINS SILVER STEVIE® AWARD IN 2016 STEVIE AWARDS FOR WOMEN IN BUSINESS
- ISPOR LAUNCHES “NEW PROFESSIONALS” NETWORK
- ISPOR 19TH ANNUAL EUROPEAN CONGRESS FOCUSES ON THE USE OF REAL-WORLD DATA IN HEALTH TECHNOLOGY ASSESSMENT
- ISPOR RECOGNIZES FIVE DISTINGUISHED RECIPIENTS OF 2016 SERVICE AWARDS AT 19TH ANNUAL EUROPEAN CONGRESS
- PLENARY 3 OF ISPOR 19TH ANNUAL EUROPEAN CONGRESS EXPLORES KEY LESSONS FROM THE INTERQUALITY PROJECT
- ISPOR 19TH ANNUAL EUROPEAN CONGRESS EXAMINES INCLUSION OF FUTURE MEDICAL COSTS IN HEALTH TECHNOLOGY ASSESSMENT GUIDELINES
- ISPOR 19TH ANNUAL EUROPEAN CONGRESS EXPLORES THE ASPIRATIONAL AND PRACTICAL ELEMENTS OF GENERATING REAL-WORLD EVIDENCE
- ISPOR 19TH ANNUAL EUROPEAN CONGRESS EXAMINES VALUE ASSESSMENT OF TRANSFORMATIVE MEDICINES IN RARE DISEASES
- ISPOR 19TH ANNUAL EUROPEAN CONGRESS FOCUSES ON EMERGING US VALUE FRAMEWORKS
- ISPOR 19TH ANNUAL EUROPEAN CONGRESS ISSUE PANEL EXPLORES ISSUE OF ADAPTIVE PATHWAYS AND PATIENT ACCESS
- PLENARY 2 OF ISPOR 19TH ANNUAL EUROPEAN CONGRESS FOCUSES ON DIFFERENTIAL PRICING OF MEDICINES IN EUROPE
- ISPOR 19TH ANNUAL EUROPEAN CONGRESS EXAMINES USE OF MULTI-CRITERIA DECISION ANALYSIS TO SUPPORT HEALTH TECHNOLOGY ASSESSMENT
- ISPOR 19TH ANNUAL EUROPEAN CONGRESS EXPLORES HOW INCENTIVES COULD SUPPORT EFFECTIVENESS RESEARCH OF MEDICAL DEVICES
- [+] October (8)
- ISPOR 19TH ANNUAL EUROPEAN CONGRESS EXPLORES HOW HTA BODIES CAN CONSIDER THE VOICE OF PATIENTS WITH RARE DISEASES
- ISPOR 19TH ANNUAL EUROPEAN CONGRESS EXAMINES NEW APPROACHES TO SURVIVAL MODELING IN ONCOLOGY
- ISPOR 19TH ANNUAL EUROPEAN CONGRESS EXPLORES EUROPEAN COOPERATION IN HEALTH TECHNOLOGY ASSESSMENT
- PLENARY 1 OF ISPOR 19TH ANNUAL EUROPEAN CONGRESS EXPLORES SYNERGIES IN HEALTH CARE
- ISPOR 19TH ANNUAL EUROPEAN CONGRESS TO FOCUS ON MANAGING ACCESS TO MEDICAL INNOVATION
- ACCOUNTING FOR FUTURE PRICE REDUCTIONS CAUSED BY INCREASING ADOPTION OF MEDICAL DEVICES: IMPACT ON HTAs
- ISPOR TASK FORCE PROVIDES RECOMMENDATIONS ON THE COLLECTION OF HEALTH-STATE UTILITY DATA IN CLINICAL STUDIES
- ISPOR’S INITIATIVE ON US VALUE ASSESSMENT FRAMEWORKS CONFERENCE DRAWS KEY HEALTH CARE STAKEHOLDERS AND THOUGHT LEADERS
- [+] September (5)
- ISPOR ANNOUNCES PLENARY SESSIONS AND SPEAKERS FOR 19TH ANNUAL EUROPEAN CONGRESS
- PLENARY 3 OF ISPOR 7TH ASIA-PACIFIC CONFERENCE EXPLORES UNIVERSAL HEALTH COVERAGE IN ASEAN
- PLENARY 2 OF ISPOR 7TH ASIA-PACIFIC CONFERENCE EXAMINES ROLE OF BIG DATA IN REGION’S HEALTH
- PLENARY 1 OF ISPOR 7TH ASIA-PACIFIC CONFERENCE EXPLORES HEALTH TECHNOLOGY ASSESSMENT IN ASIA
- GLOBAL TRAVEL AND THE ZIKA VIRUS
- [+] August (6)
- ISPOR SPECIAL INTEREST GROUP RECOMMENDS CHANGES TO HEALTH TECHNOLOGY ASSESSMENTS FOR MOLECULAR DIAGNOSTICS
- US HEALTH CARE SYSTEM BEGINS TO EMBRACE COST EFFECTIVENESS AS A CENTRAL COMPONENT OF “VALUE”
- ISPOR 7th ASIA-PACIFIC CONFERENCE TO CONCENTRATE ON PHARMACOECONOMICS AND OUTCOMES RESEARCH
- ISPOR OFFERING NEW MEMBER WEBINAR
- ISPOR ANNOUNCES STAKEHOLDER CONFERENCE FOR INITIATIVE ON US VALUE ASSESSMENT FRAMEWORKS
- ISPOR CEO NANCY BERG NAMED A PHARMAVOICE 100
- [+] July (3)
- [+] June (6)
- UNRESTRICTED MEDICAID ACCESS TO NOVEL HEPATITIS C THERAPIES MAY REDUCE OVERALL COSTS, IMPROVE OUTCOMES
- ISPOR TASK FORCE PROVIDES GUIDANCE ON STATISTICAL METHODS FOR ANALYZING PATIENT PREFERENCE DATA
- VALUE IN HEALTH JOURNAL SHOWS SIGNIFICANT GROWTH IN IMPACT
- ISPOR ANNOUNCES PLENARY SESSIONS AND SPEAKERS FOR 7th ASIA-PACIFIC CONFERENCE
- ISPOR 21st ANNUAL INTERNATIONAL MEETING CONVENED KEY HEALTH CARE STAKEHOLDERS IN WASHINGTON, DC
- NANCY BERG NAMED ONE OF 2016 PM360 ELITE 100
- [+] May (15)
- ISPOR 21ST ANNUAL INTERNATIONAL MEETING WORKSHOP EXAMINES METHODOLOGIES FOR EVALUATING GEOSPATIAL ACCESS
- BEST PODIUM AND POSTER PRESENTATIONS AWARDED AT ISPOR ANNUAL INTERNATIONAL MEETING
- PLENARY 3 OF ISPOR 21ST ANNUAL INTERNATIONAL MEETING EXPLORES REGULATORY AND LEGISLATIVE ISSUES IN HEALTH OUTCOMES RESEARCH
- ISPOR 21ST ANNUAL INTERNATIONAL MEETING ISSUE PANEL EXPLORES PATIENT PERSPECTIVES OF VALUE ASSESSMENT FRAMEWORKS IN ONCOLOGY
- ISPOR 21ST ANNUAL INTERNATIONAL MEETING ISSUE PANEL FOCUSES ON PRECISION MEDICINE AND ITS IMPACT ON OUTCOMES RESEARCH
- ISPOR 21ST ANNUAL INTERNATIONAL MEETING WORKSHOP EXPLORES HOW TO MAKE PATIENTS AS PARTNERS IN RESEARCH A REALITY
- ISPOR 21ST ANNUAL INTERNATIONAL MEETING ISSUE PANEL CONSIDERS MCDA AS A POSSIBLE NEW PARADIGM IN HEALTH CARE DECISION MAKING
- PLENARY 2 OF ISPOR 21ST ANNUAL INTERNATIONAL MEETING FOCUSES ON IMPACT OF BEHAVIORAL ECONOMIC MODELS ON MEDICAL DECISION MAKING
- ISPOR RECOGNIZES 2016 AWARDS PROGRAM RECIPIENTS AT 21ST ANNUAL INTERNATIONAL MEETING
- ISPOR 21ST ANNUAL INTERNATIONAL MEETING WORKSHOP EXPLORES RISK-SHARING AGREEMENTS
- ISPOR 21ST ANNUAL INTERNATIONAL MEETING ISSUE PANEL CONSIDERS THE USE OF REAL-WORLD EVIDENCE IN HEALTH CARE DECISION MAKING
- PLENARY 1 OF ISPOR 21ST ANNUAL INTERNATIONAL MEETING FOCUSES ON ISSUES SURROUNDING ACCELERATED DRUG APPROVALS
- ISPOR INTERNATIONAL MEETING TO FOCUS ON HEALTH CARE VALUE, AFFORDABILITY, AND PATIENT CENTEREDNESS
- ISPOR ANNOUNCES ESTABLISHMENT OF NEW INITIATIVE ON VALUE ASSESSMENT FRAMEWORKS
- ISPOR PUBLISHES NEW GLOBAL HEALTH CARE SYSTEMS ROAD MAP: AUSTRALIA MEDICAL DEVICES
- [+] April (8)
- ISPOR EXPANDS LEADERSHIP TEAM WITH CHIEF SCIENCE OFFICER
- ISPOR LAUNCHES NEW CAREER CENTER
- ISPOR PUBLISHES TASK FORCE REPORT #2 ON MULTIPLE CRITERIA DECISION ANALYSIS
- ISPOR ATTENDING AMCP 2016 THIS APRIL
- ISPOR ATTENDING 2016 HTAi ANNUAL MEETING IN TOKYO THIS MAY
- ISPOR SPONSORING SESSION AT DIA 2016 THIS JUNE
- ISPOR “ON THE ROAD” IN 1ST QUARTER 2016
- ISPOR ANNOUNCES NEW HTA TRAINING PROGRAM
- [+] March (1)
- [+] February (2)
- [+] January (3)
- [+] 2015 (61)
- [+] December (3)
- [+] November (11)
- ISPOR 18th ANNUAL EUROPEAN CONGRESS CONCLUDES
- ISPOR RECOGNIZES 2015 AWARDS PROGRAM RECIPIENTS AT 18th ANNUAL EUROPEAN CONGRESS
- ISPOR’s 3rd PLENARY OF 18th ANNUAL EUROPEAN CONGRESS DISCUSSES MULTI-CRITERIA DECISION ANALYSIS (MCDA)
- ISPOR 18th ANNUAL EUROPEAN CONGRESS FEATURES WORKSHOP ON OPTIMIZING PATIENT INVOLVEMENT IN PAYER HEALTH CARE DECISIONS
- ISPOR’s 2nd PLENARY OF 18th ANNUAL EUROPEAN CONGRESS EXPLORES EVOLUTION OF OUTCOMES RESEARCH IN HEALTH CARE
- ISPOR OUTLINES NEW STRATEGIC VISION AT 18th ANNUAL EUROPEAN CONGRESS
- ISPOR 18th ANNUAL EUROPEAN CONGRESS ISSUE PANEL EXAMINES SYNERGY BETWEEN HTA AND REGULATORY AGENCIES
- ISPOR 18th ANNUAL EUROPEAN CONGRESS ISSUE PANEL EXPLORES ROLE OF ECONOMIC EVALUATION IN PRICING & REIMBURSEMENT OF MEDICINES
- ISPOR’s 1st PLENARY OF 18th ANNUAL EUROPEAN CONGRESS FOCUSES ON LIFECYCLE APPROACH TO DECISION MAKING ON HEALTH TECHNOLOGIES
- ISPOR PUBLISHES NEW TASK FORCE REPORT ON CLINICAL OUTCOME ASSESSMENTS (COAs)
- ISPOR EUROPEAN CONGRESS FOCUSES ON “IMPACTING HEALTH DECISION MAKING WITH OUTCOMES RESEARCH”
- [+] October (5)
- INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS AND OUTCOMES RESEARCH (ISPOR) EXPANDS LEADERSHIP TEAM
- STUDY REVEALS SIGNIFICANT GLOBAL VARIATION IN THE DEFINITION OF THE TERM “RARE DISEASE”
- ISPOR ANNOUNCES CALL FOR NOMINATIONS
- ATLAS AWARD TO BE PRESENTED TO AUTHORS OF ISPOR’s VALUE IN HEALTH ARTICLE
- ISPOR 18th ANNUAL EUROPEAN CONGRESS REGISTRATION AT RECORD HIGH
- [+] September (5)
- [+] August (2)
- [+] July (14)
- THE FOURTH HURDLE – CAN IT BE SIMPLIFIED?
- METFORMIN SHOWS UNDOUBTEDLY THE FIRST-LINE POSITION IN THE TREATMENT OF TYPE 2 DIABETES IN CHINA
- AUSTRALIA - CANCER DRUG REIMBURSEMENT ON PHASE 2 DATA
- TREATMENT PREFERENCES FOR BLOOD THINNERS: COMPARISON BETWEEN PHYSICIANS AND PATIENTS WITH ATRIAL FIBRILLATION IN THE U.S. AND JAPAN
- IMPACT OF HEART ATTACKS ON QUALITY OF LIFE OF MALAYSIAN PATIENTS
- PHILIPPINE HEALTH INSURANCE CORPORATION (PHILHEALTH) COVERAGE FOR COMMUNITY-ACQUIRED PNEUMONIA – IS IT ENOUGH?
- THE PROBLEM OF REIMBURSEMENT FOR SINGLE-USE DEVICES IN ASIA-PACIFIC COUNTRIES
- ENSURING THE FUTURE FOR CHINA’S ESSENTIAL DRUG POLICY
- ASSURE SAFETY IN INTRAVENOUS MEDICATION USE IN CHINA
- THE GROWING USE OF COST-UTILITY ANALYSIS IN ASIA
- DO ANTI-EPILEPTIC DRUGS USED IN TREATMENT OF EPILEPSY INFLUENCE QUALITY OF LIFE [QOL]?
- IS NEWLY INVENTED THROMBIN-RECEPTOR ANTAGONIST (TRA) EFFECTIVE AND SAFE ENOUGH TO COMBAT WITH HEART DISEASE?
- VALUE IN HEALTH IMPACT FACTOR RECENTLY ANNOUNCED - 13% INCREASE!
- ISPOR ANNOUNCES 2015-2016 BOARD OF DIRECTORS
- [+] June (2)
- [+] May (4)
- MAPPING THE CLINICAL COPD QUESTIONNAIRE ONTO EQ-5D VALUES
- SHOULD COST-EFFECTIVENESS BE INCLUDED IN CLINICAL TREATMENT GUIDELINES?
- THE STATE OF THE LEARNING HEALTH CARE SYSTEM: HAS THE INVESTMENT IN USING ELECTRONIC DATA TO TRACK PATIENTS ACROSS HEALTH CARE PROVIDERS AND TIME PAID OFF?
- ISPOR CELEBRATES 20 YEARS OF GROWTH AND ACHIEVEMENT AT 2015 ANNUAL INTERNATIONAL MEETING
- [+] April (4)
- WHAT IS THE IMPACT OF ADDING EXTRA HEALTH DIMENSIONS TO THE EQ-5D?
- HEALTH CARE DECISION MAKERS OPEN FOR PUBLIC AND PATIENT INVOLVEMENT IN COVERAGE DECISIONS
- IDENTIFYING THE FACTORS THAT ENHANCE POSITIVE DRUG REIMBURSEMENT RECOMMENDATION IN SCOTLAND
- MEASURING HEALTH-RELATED QUALITY OF LIFE BY EXPERIENCES
- [+] March (6)
- MAINTENANCE AND CONSOLIDATION THERAPIES: COST-EFFECTIVE STRATEGIES TO PROLONG REMISSION IN PATIENTS WITH FOLLICULAR LYMPHOMA
- NEW FRAMEWORK MEASURES FAIRNESS WHEN DISTRIBUTING VACCINES
- INDUSTRY AND GOVERNMENT LEADERS OUTLINE POTENTIAL FOR SOCIAL MEDIA TO ACCELERATE PRO DEVELOPMENT
- ANTICIPATING TREATMENT NON-PERSISTENCE THROUGH AN INNOVATIVE CONCEPTUAL FRAMEWORK
- ATORVASTATIN SHOWN COST-EFFECTIVE FOR PREVENTING CARDIOVASCULAR DISEASES
- ISPOR BOARD OF DIRECTORS ELECTION 2015
- [+] February (1)
- [+] January (4)
- PARENTS OF CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS EXPRESS STRONG WILLINGNESS TO PAY FOR BIOLOGIC THERAPIES
- DISCOVERING THE COSTS OF USING DIFFERENT MAPPING ALGORITHMS
- ISPOR 2015 SCIENTIFIC AWARDS - CALL FOR NOMINATIONS
- SUCCESS FEE: A NOVEL TOOL FOR THE SUSTAINABILITY OF NOVEL EXPENSIVE THERAPIES
- [+] 2014 (95)
- [+] December (3)
- [+] November (6)
- THE VALUE OF GENETIC DIVINATION – STATED PREFERENCES FOR PERSONALIZED INFORMATION FOR REDUCING MORTALITY RISKS
- EXTRACELLULAR MATRIX IS A COST EFFECTIVE OPTION FOR THE MANAGEMENT OF VENOUS LEG ULCERS
- BIOLÓGICOS PARA ARTRITIS PSORIÁSICA EN URUGUAY
- HOW DO PUBLIC HEALTH INSTITUTIONS DECIDE WHICH HEALTH TECHNOLOGIES ARE AVAILABLE IN MEXICO?
- ‘ONE SIZE FITS ALL’ GUIDELINE NOT COST-EFFECTIVE FOR ALL WOMEN WITH EARLY BREAST CANCER
- HOW MUCH DO PESTICIDE INTOXICATIONS COST IN CHILE?
- [+] October (14)
- WHAT`S GOING ON WITH THE TURKISH ORPHAN DRUGS MARKET?
- THE IMPACT OF PRICE REDUCTIONS AND COST-SHARING RATES IN GREECE
- WORK PRODUCTIVITY IN RHEUMATIC DISEASES AND PSORIASIS
- IS FIDAXOMICIN COST-EFFECTIVE FOR CLOSTRIDIUM DIFFICILE INFECTION?
- POORLY CONTROLLED ASTHMA HAS SIZEABLE FINANCIAL IMPACT IN LATIN AMERICA
- ISPOR ADDRESSES NEW CHALLENGES FOR IMPROVING EUROPEAN HEALTH CARE AT ANNUAL EUROPEAN CONGRESS
- ARE HEALTH CARE PROCEDURES ALWAYS VALUABLE TO PATIENTS?
- LOW INCOME DECREASES ADHERENCE TO MEDICATIONS
- HOW MUCH DOES RUSSIA SPEND ON CANCER?
- WHAT IS THE COST OF RHEUMATOID ARTHIRIS IN THE CZECH REPUBLIC?
- WHAT IS THE REAL COST OF RISKY BEHAVIORS TO SOCIETY?
- ARE WARFARIN AND ASPIRIN COST-EFFECTIVE IN AORTIC VALVE REPLACEMENTS IN EGYPT?
- COST-EFFECTIVENESS VS. COST-UTILITY ANALYSES – WHEN IS EACH USED, AND HOW DO THEY DIFFER?
- MAPPING THE NOTTINGHAM HEALTH PROFILE ONTO EUROQOL-5D IN PATIENTS WITH DIABETES
- [+] September (10)
- MODELS TO PREDICT HEALTH UTILITIES IN PATIENTS WITH LOW BACK PAIN
- THE NOCTURIA IMPACT DIARY: A NEW VALIDATED SELF-REPORTED IMPACT ASSESSMENT TOOL
- SENSOR-AUGMENTED INSULIN PUMP THERAPY WITH AUTOMATED INSULIN SUSPENSION IN HIGH RISK TYPE 1 DIABETES PATIENTS LIKELY COST EFFECTIVE
- ¿LA EVALUACIÓN DE INSUMOS, IMPACTA EN LA OPTIMIZACIÓN DE RECURSOS?
- LOS COSTOS DE LA ENFERMEDAD LABORAL: EL CASO DEL SÍNDROME DEL TÚNEL DEL CARPO
- IS SUFFICIENT DATA AVAILABLE TO MEET HEALTH-ECONOMIC REQUIREMENTS ACROSS EUROPE?
- COST ESTIMATION OF HIV-INFECTION IN A CONSTRAINED FISCAL ENVIRONMENT
- HOW MUCH DOES IT REALLY COST HEALTH FACILITIES IN GHANA TO TREAT BURULI ULCER WOUNDS?
- HEALTH CARE REFORMS AND ACCESS TO MEDICINES IN ETHIOPIA
- THE INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS AND OUTCOMES RESEARCH ANNOUNCES NEW CEO AND EXECUTIVE DIRECTOR
- [+] August (7)
- ISPOR Asia-Pacific Conference in Beijing, China to Focus on Health Care Reform, Big Data, and Patients in Asia
- ¿LA EVALUACIÓN DE INSUMOS, IMPACTA EN LA OPTIMIZACIÓN DE RECURSOS?
- LOS COSTOS DE LA ENFERMEDAD LABORAL: EL CASO DEL SÍNDROME DEL TÚNEL DEL CARPO
- HEALTH-RELATED QUALITY OF LIFE MEASURES FAIL TO CAPTURE PART OF THE BROADER IMPACT OF DISEASE ON SUBJECTIVE WELL-BEING
- GOOD NEWS FOR SUFFERERS OF CHRONIC AIRWAY DISEASE
- HOW DO WE IMPROVE MODELS THAT ARE NAÏVE TO REAL-WORLD ADHERENCE?
- GOOD NEWS FOR SUFFERERS OF CHRONIC AIRWAY DISEASE
- [+] July (3)
- [+] June (21)
- Should Governments Invest in Specialist Care for Periodontitis?
- One More Brick On The Back Of Drowning National Health Care System
- Interferon-Alfa Therapy Is Associated With A High Adverse Event Burden Among Hepatitis C Patients In Japan
- Sentinel Node Biopsy: The Future For Early Breast Cancer
- Partially Hydrolyzed Formula (PHF-W) Predicted To Reduce The Burdens Of Atopic Dermatitis
- Can HIV Patients Assess Their Own Quality of Life?
- Models To Predict Cardiovascular Disease Risk In Vietnam
- Pros And Cons Of Vietnamese Socialization Of Health Care
- What Does the Future of Health Technology Assessment Hold for Mainland China, Japan, South Korea, and Taiwan?
- A Cost-Effective Antibiotic For Hospital Acquired Pneumonia
- Is EGFR Mutation Testing Worth It In Non-Small Cell Lung Cancer?
- Is CTC Implementation Cost-Effective for Colorectal Cancer?
- Inconsistency Among Utility Values in Japanese Studies –Are All QALYs Created Equal?
- Cost-Utility Analysis Of Erythropoietin For Hemodialysis Patients
- Is It Time to Introduce Pneumococcal Vaccine to the National Immunization Programme in Malaysia?
- Pharmacoeconomics And Outcomes Research Is Evolving In Asia
- Pharmacoeconomics in China: Where We Are And Where Are We Going?
- Collaboration Between Regulators And HTA Organizations To Improve Health Care Decision Making
- Potential Common Benchmark For Assessing New Diabetes Treatments
- Reducing Dietary Salt Intake In The English Population To Prevent Coronary Heart Disease – What Works?
- How Does a Drug Get Reimbursed in Iran?
- [+] May (8)
- Cost-Savings In Effective Clinical Reminders For HIV Testing
- The International Society For Pharmacoeconomics And Outcomes Research Examines The Role Of Big Data In Health Care Decision Making
- Differences Between Patients' And General Population's Measures Of Quality Of Life Vary Dependent Upon Health Problems
- A New Approach To Korea's Reimbursement Coverage And Pricing Rules For Medical Devices Long Overdue
- Risk Sharing To Fund Innovative Health Care Technologies: Lessons From The Airline Industry
- Improving Clinical Trial Participation Through Patient-Centered Trial Design
- An Updated Economic Analysis Of Treatment Costs Related To Parenteral Nutrition
- HITECH: Electronic Prescribing Less Costly, Improves Medication Safety
- [+] April (5)
- Insight into HTA Decision Making Behind the EU's Current Crop of Biosimilars
- One Treatment Does Not Fit All When It Comes To Low Back Pain
- Assessing Patients' Performance Following Primary Total Knee Replacement
- Estimation Of Potential Gain In Quality Of Life From Early Detection Of Cervical Cancer
- Drug Initiation: Major Issue In Long-Term Adherence To Medication Therapy
- [+] March (11)
- Linking Profile To Preference-Based Measures - Don't Regress
- Modeling Long-Term Life Expectancy And Associated Medical Costs For Acute Myeloid Leukaemia (AML) Patients
- Should All Type 2 Diabetes Patients be Prescribed Preventive Statin Treatment?
- Does Outcomes Research Reduce Policy Maker Uncertainty?
- An Open-Source Model For The Economic Evaluation Of Treatment Strategies In Depression
- The QALY Model Upside-Down
- How to Measure Preferences Over Health Care Options?
- Does an Official Positive List of Medical Devices Exist?
- A Terapia Estendida Para A Hepatite Crônica C
- Dengue In Latin America And The Caribbean Countries: The Cases Increased And Changes In The Circulation Of The Virus
- Que Tanto Cuesta El Tratamiento de VIH/SIDA en México?
- [+] February (2)
- [+] January (5)
- Does Medicare Supplemental Insurance Protect Beneficiaries With Cancer?
- TPMT Genotyping Prior to Azathioprine: a Cost-Effective Use of Resources?
- Challenges In Valuing The Impact Of Sexually Transmitted Infections
- Quality Of Life In Heart Patients: The Way You Measure Drives The Results
- Bayesian Meta-Analysis Of Diverse Sources Of Evidence Can Expedite Health Technology Assessments
- [+] 2013 (87)
- [+] November (3)
- [+] October (17)
- Payers And Regulators Raise The Bar In Europe
- Is Boceprevir Cost-Effective for Previously Treated Hepatitis C Patients?
- Communist Era Beliefs Are Constraining Privatisation Of Health In Poland
- What is the Cost of Diarrheal Illness?
- What is the Role of ISPOR Regional Chapters in Health Technology Implementation?
- Curbing Drug Costs: Should Hungary Become A Role Model?
- Electronic Referrals In Greece: When Common Sense Becomes Innovation
- Can Information Technology Systems Effectively Compile Reimbursement Lists?
- Can Balkan Health Care Budgets Withstand Overconsumption of Radiology Services?
- Chickenpox - An Innocent Looking Threat
- In Data We Trust
- Realizing The Burden Of Invasive Pneumococcal Disease In Developing Countries
- Patients With AIDS Report Improved Quality Of Life
- Challenges In Estimation Of Children’s Quality Of Life
- Recommendations For Reporting Pharmacoeconomic Evaluations Important To Egypt
- Can Pharmaceutical Care Interventions Improve Type 2 Diabetes Management?
- New European Policies & Patients Stimulate Change in New Health Care Technology Adoption
- [+] September (9)
- Study Applies Timely Cost-Effectiveness Analysis To State Breast Cancer Screening Program
- Issues And Challenges When Pharma Works With Regulators & HTA Agencies
- Psoriasis Symptom Diary© Provides Important Patient Perspective On Symptoms And Disease Impact For Efficacy Endpoint Evaluation
- What Is The Best Approach To Hip Replacement For Different Patient Groups?
- How Do I Know If My Cognition Is Affected After My Cancer Treatment?
- A Case Study Of Surrogate Outcomes For Overall Survival In The Treatment Of Chronic Myelogenous Leukemia
- How Difficult Are Diagnostic And Screening Tests For Patients?
- Hepatitis C: Is Rationalization of Health Care Expenditure Possible?
- Trial Of Labor After Cesarean Found To Be Cost-Effective When Considering Long-Term Consequences
- [+] August (2)
- [+] July (6)
- Patients' Age Is Important When Setting Priorities
- Developing Countries Need To Produce Their Own Valuation Of Quality Of Life
- Insights For Helping Get First Medication Prescriptions Filled
- Let’s Think for a Minute: Do Respondents Need Time to Deliberate When Undertaking Health State Valuation Exercises?
- Education Proves More Effective Than Reminders At Improving Hypertension Patient Medication Adherence
- Personalized Medicine: Genomic Test For Breast Cancer Recurrence Found To Be Cost-Effective
- [+] June (6)
- Quality Measures Developed For Childhood Cancer Care Systems
- Italian Social Tariffs For QALYs Calculation Are Now Available
- Reviewing Evidence For Use In Cost Effectiveness Models
- Different Symptoms Important to Kidney Cancer Patients and Clinicians
- Valuing The Intangible Impacts Of Informal Care
- Willingness To Pay For Diagnostic Tests
- [+] May (18)
- Nice’s Scientific Credibility Compromised By Recent Amendment To Appraisal Methods
- Pharmacoeconomic Guidelines Unclear On Dealing With Patient Differences
- Checklist For Identifying Cancer Patients In Secondary Data
- Evaluating Diagnostic Strategies Involving Multiple Tests
- A Value Proposition For Specialty Medications
- It Matters How You Ask: Parsing Out Pros And Other COA Items
- Improved Estimations Of Cost-Effectiveness For Ovarian Cancer
- Illustrating Potential Efficiency Gains From Using Cost-Effectiveness Evidence To Reallocate Medicare Expenditures For Medical Technology
- Patients Willing To Pay More For Avoiding Symptoms Of GERD
- Is Statin Cost Effective in Japan for Primary Prevention of Coronary Artery Disease?
- The Economics Of Lowering Cholesterol Among Filipinos
- Why Does Anti-Infective Drug Expenditure Increase In China?
- Clinical Pharmacy Education Improved Infection Management In Chronic Kidney Disease
- What Are Direct Medical Costs Of Vision Impairment?
- Quality-of-Life Among Non-Prescription Medicine Consumers - Are They Different?
- The Current Status Of Ulcerative Colitis In Taiwan
- What Are The Important Factors In Selecting TCM?
- What Makes You Purchase OTC Medicines?
- [+] April (1)
- [+] March (9)
- Three CHEERS For Transparency In Health Care Economic Study Information
- The Health Care Costs Of Cystic Fibrosis
- Patients Undergoing Laparoscopic Surgery Recover Faster
- National Minority Vaccination Program Likely To Be Cost-Effective
- Cost-Effective Alternative For Chronic Low Back Pain
- Is It Cost-Effective To Use A Diagnostic Aid To Diagnose Skin Lesions In Primary Care?
- Innovative Methods Can Identify Differential Responders To Treatment
- Patient's Needs For Medication Adherence Are Still Unclear
- Bayesian Methods Can Help To Bring Science Closer To Policy
- [+] February (1)
- [+] January (15)
- Patients Pay The Bill For Delaying Hip Replacement
- Common Adverse Effects And Health Care Costs In HIV Patients On Antiretroviral Therapies
- Need For Speed In Value Of Information Analysis In Health Care: Some New Developments
- Expecting A Lot Of Missing Data In Your Resource Use Questionnaire? Give Patients A Resource Use Log Too!
- The Most Disabling Form Of Migraine, Chronic Migraine, Is Costly To Employers
- Is The Public Engaged In Health Technology Assessment?
- New Approach To “Mapping” Treatment Effects To Generic Health-Related Quality Of Life Scales
- Testing Patient Satisfaction With Treatments
- Proton Pump Inhibition Most Cost-Effective Preventative Approach In Stress Ulcer Bleeding
- Recommendations For Estimating Utility Values From Other Health Measures
- Economic Efficiency Of Countries' Clinical Review Processes
- Does the Future Belong to MCDA?
- All Sources Of Value Are Not Captured By All Models
- How to Get into Turkey's Medical Device Market?
- Genomic Test Cost-Effectively Diagnoses Challenging Cancer Cases
- [+] 2012 (40)
- [+] December (6)
- New Approach To Developing Preference Based Measures
- Comparing Different Methods for Measuring Benefits for Economic Evaluation
- Measuring Health-Related Quality Of Life (HRQoL) In Leukemia Patients
- Innovative Methods Uncover Differential Responders To Treatment
- Having Diabetes Mellitus May Cost The Patient 11.1 Years Of Healthy Life
- More Sobriety Checkpoints Needed In Thailand
- [+] November (4)
- [+] October (1)
- [+] September (14)
- Value Of Molecular Diagnosis Of Thyroid Cancer
- Self-Care Or Professional Help? The Role Of Symptom Severity
- The Impact On Carers Is Routinely Ignored In Value For Money Assessments
- First Ever Daily Quality Of Life Measurements Studied In Hemophilia Patients
- New Statistical Method Provides Timely Comparative Effectiveness Research
- Drugs For Rare Diseases: How To Fund Them?
- Modeling: Everything You Wanted To Know, But Were Afraid To Ask
- Conception Of A Model
- Models In A State Of Transition
- Modeling And Discrete Events
- How To Be A Dynamic Model
- Uncertainty Of Modeling
- Models Exposed
- Research Shows How To Avoid Misleading With Statistics
- [+] August (4)
- [+] July (3)
- [+] June (8)
- FDA Actions Against Misleading Health Economic Promotions, 2002-2011
- Pricing The Side Effects Of Prostate Cancer Treatment
- How To Use Evidence For Cost-Effectiveness Modeling
- Bivalent HPV Vaccine - Best Value For Money
- Do Patients Value Consulting A Prescribing Pharmacist?
- Whose Values In Adolescent Health: Adults Or Adolescents?
- Psychotherapy Safer In The Longer-Term Management Of Pediatric Major Depressive Disorder
- New Data Demonstrate The Cost-Effectiveness Of Bendamustine In The Treatment Of Chronic Lymphocytic Leukaemia (CLL)
Categories
Tags
Annual European Congress
Australia
cancer
cost-effectiveness analysis
cost-utility analyses
diabetes
drug pricing
EQ-5D
health-related quality of life
health economics
health outcomes
health policy
health technology assessment
HEOR
HTA
ISPOR
ISPOR 2018
ISPOR Awards
ISPOR International Meeting
Markov model
modeling
multi-criteria decision analysis
Nancy Berg
new methods: economic
new methods: outcomes
observational studies
oncology
outcomes measure
outcomes research
patient-reported outcomes
patients
pharmacoeconomics
policy review
PR
QALY
real-world data
real-world evidence
reimbursement
Task Force Report
The Netherlands
United Kingdom
United States
utility
Value Assessment Frameworks
Value in Health
